Hypnotics and mortality in an elderly general population: a 12-year prospective study

BMC Medicine

Yves Dauvilliers⁴  Karen Ritchie¹  Alain Besset²  Jacqueline Scali³  Karine Pérès⁵  Claudine Berr²  Marie-Laure Ancelin²  Isabelle Jaussent² 

[1] Faculty of Medicine, Imperial College, London, UK;Université Montpellier 1, Montpellier F-34000, France;Inserm, U1061, Montpellier F-34000, France;Service de Neurologie, Hôpital Gui-de-Chauliac, 80 avenue Augustin Fliche, Montpellier cedex 5 34295, France;ISPED, Centre Inserm U897, Université Bordeaux, Bordeaux F-33000, France

关键词: Sleep disorders;    Mortality;    Hypnotics;    Elderly;    Cohort studies;   

Others  :  855679
DOI  :  10.1186/1741-7015-11-212

 received in 2013-07-25, accepted in 2013-09-09,  发布年份 2013

【 摘 要 】

Background

Hypnotics are widely used by the elderly, and their impact on mortality remains controversial. The inconsistent findings could be due to methodological limitations, notably the lack of control for underlying sleep symptoms or illness associated with hypnotic use, for example, insomnia symptoms and excessive daytime sleepiness, depression and anxiety. Our objective was to examine the association between the use of hypnotics and mortality risk in a large cohort of community-dwelling elderly, taking into account a wide range of potential competing risks including sociodemographic characteristics, lifestyle, and chronic disorders as well as underlying psychiatric disorders and sleep complaints.

Methods

Analyses were carried out on 6,696 participants aged 65 years or older randomly recruited from three French cities and free of dementia at baseline. Adjusted Cox proportional hazards models with delayed entry, and age of the participants as the time scale, were used to determine the association between hypnotic use and 12-year survival.

Results

At baseline, 21.7% of the participants regularly used at least one hypnotic. During follow-up, 1,307 persons died, 480 from cancer and 344 from cardiovascular disease. Analyses adjusted for study center, age and gender showed a significantly greater risk of all-cause and cardiovascular-related mortality with hypnotics, particularly benzodiazepines, and this increased with the number of hypnotics used. None of these associations were significant in models adjusting for sociodemographic and lifestyle characteristics, chronic disorders including cardiovascular pathologies, sleep and psychiatric disorders. Results remained unchanged when duration of past hypnotic intake or persistent versus intermittent use during follow-up were taken into account.

Conclusions

When controlling for a large range of potential confounders, the risk of mortality was not significantly associated with hypnotic use regardless of the type and duration. Underlying psychiatric disorders appear to be the principal confounders of the observed association.

【 授权许可】

   
2013 Jaussent et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC: Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc 2009, 57:761-789.
• [2]Morin CM, Benca R: Chronic insomnia. Lancet 2012, 379:1129-1141.
• [3]Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C: Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006, 7:123-130.
• [4]Ohayon MM, Dauvilliers Y, Reynolds CF 3rd: Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology. Arch Gen Psychiatry 2012, 69:71-79.
• [5]Blachier M, Dauvilliers Y, Jaussent I, Helmer C, Ritchie K, Jouven X, Tzourio C, Amouyel P, Besset A, Ducimetiere P, Empana JP: Excessive daytime sleepiness and vascular events: the Three City Study. Ann Neurol 2012, 71:661-667.
• [6]Jaussent I, Empana JP, Ancelin ML, Besset A, Helmer C, Tzourio C, Ritchie K, Bouyer J, Dauvilliers Y: Insomnia, daytime sleepiness and cardio-cerebrovascular diseases in the elderly: a 6-year prospective study. PLoS One 2013, 8:e56048.
• [7]Jaussent I, Bouyer J, Ancelin ML, Akbaraly T, Peres K, Ritchie K, Besset A, Dauvilliers Y: Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly. Sleep 2011, 34:1103-1110.
• [8]Mellinger GD, Balter MB, Uhlenhuth EH: Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985, 42:225-232.
• [9]Ohayon MM, Caulet M: Psychotropic medication and insomnia complaints in two epidemiological studies. Can J Psychiatry 1996, 41:457-464.
• [10]Ohayon MM, Caulet M, Priest RG, Guilleminault C: Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 1998, 51:273-283.
• [11]Quera-Salva MA, Orluc A, Goldenberg F, Guilleminault C: Insomnia and use of hypnotics: study of a French population. Sleep 1991, 14:386-391.
• [12]Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004, 18:297-328.
• [13]Empana JP, Dauvilliers Y, Dartigues JF, Ritchie K, Gariepy J, Jouven X, Tzourio C, Amouyel P, Besset A, Ducimetiere P: Excessive daytime sleepiness is an independent risk indicator for cardiovascular mortality in community-dwelling elderly: the three city study. Stroke 2009, 40:1219-1224.
• [14]Carrière I, Ryan J, Norton J, Scali J, Stewart R, Ritchie K, Ancelin M: Anxiety and risk of death in the elderly: the Esprit study. Br J Psychiatry 2013. in press
• [15]Ryan J, Carriere I, Ritchie K, Stewart R, Toulemonde G, Dartigues JF, Tzourio C, Ancelin ML: Late-life depression and mortality: influence of gender and antidepressant use. Br J Psychiatry 2008, 192:12-18.
• [16]Kojima M, Wakai K, Kawamura T, Tamakoshi A, Aoki R, Lin Y, Nakayama T, Horibe H, Aoki N, Ohno Y: Sleep patterns and total mortality: a 12-year follow-up study in Japan. J Epidemiol 2000, 10:87-93.
• [17]Phillips B, Mannino DM: Does insomnia kill? Sleep 2005, 28:965-971.
• [18]Hays JC, Blazer DG, Foley DJ: Risk of napping: excessive daytime sleepiness and mortality in an older community population. J Am Geriatr Soc 1996, 44:693-698.
• [19]Rumble R, Morgan K: Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc 1992, 40:787-791.
• [20]Hausken AM, Skurtveit S, Tverdal A: Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population. Pharmacoepidemiol Drug Saf 2007, 16:913-918.
• [21]Kripke DF, Langer RD, Kline LE: Hypnotics’ association with mortality or cancer: a matched cohort study. BMJ Open 2012, 2:e000850.
• [22]Mallon L, Broman JE, Hetta J: Is usage of hypnotics associated with mortality? Sleep Med 2009, 10:279-286.
• [23]Belleville G: Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey. Can J Psychiatry 2010, 55:558-567.
• [24]Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR: Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry 2002, 59:131-136.
• [25]Kripke DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L: Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998, 43:687-693.
• [26]3C Study Group: Vascular factors and risk of dementia: design of the three-city study and baseline characteristics of the study population. Neuroepidemiol 2003, 22:316-325.
• [27]Alperovitch A, Bertrand M, Jougla E, Vidal JS, Ducimetiere P, Helmer C, Ritchie K, Pavillon G, Tzourio C: Do we really know the cause of death of the very old? Comparison between official mortality statistics and cohort study classification. Eur J Epidemiol 2009, 24:669-675.
• [28]World Health Organization: International Statistical Classification of Diseases and Related Health Problems. 10th edition. Geneva; Switzerland: WHO; 1992.
• [29]Radloff LS: The CES-D Scale: a self-report depression scale for research in the general population. App Psychol Measure 1977, 1:385-401.
• [30]Spielberger C: Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto, CA: Consulting Psychologists Press; 1983.
• [31]Folstein MF, Folstein SE, McHugh PR: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
• [32]World Health Organization: International Classification of Functioning, Disability and Health. Geneva, Switzerland: WHO; 2001.
• [33]Jaussent I, Dauvilliers Y, Ancelin ML, Dartigues JF, Tavernier B, Touchon J, Ritchie K, Besset A: Insomnia symptoms in older adults: associated factors and gender differences. Am J Geriatr Psychiatry 2011, 19:88-97.
• [34]World Health Organization: World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO; 2000.
• [35]Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF: Modelling age-specific risk: application to dementia. Stat Med 1998, 17:1973-1988.
• [36]Thiebaut AC, Benichou J: Choice of time-scale in Cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med 2004, 23:3803-3820.
• [37]Hublin C, Partinen M, Koskenvuo M, Kaprio J: Sleep and mortality: a population-based 22-year follow-up study. Sleep 2007, 30:1245-1253.
• [38]Jaussent I, Bouyer J, Ancelin ML, Berr C, Foubert-Samier A, Ritchie K, Ohayon MM, Besset A, Dauvilliers Y: Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep 2012, 35:1201-1207.
• [39]Billioti De Gage S, Begaud B, Bazin F, Verdoux H, Dartigues JF, Peres K, Kurth T, Pariente A: Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012, 345:e6231.
• [40]Guilleminault C: Benzodiazepines, breathing, and sleep. Am J Med 1990, 88:25S-28S.
• [41]MacDonald JB, MacDonald ET: Nocturnal femoral fracture and continuing widespread use of barbiturate hypnotics. Br Med J 1977, 2:483-485.
• [42]Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ 3rd: Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987, 316:363-369.
• [43]Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD: Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 2005, 53:955-962.
• [44]Brassington GS, King AC, Bliwise DL: Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years. J Am Geriatr Soc 2000, 48:1234-1240.
• [45]Stone KL, Ancoli-Israel S, Blackwell T, Ensrud KE, Cauley JA, Redline S, Hillier TA, Schneider J, Claman D, Cummings SR: Actigraphy-measured sleep characteristics and risk of falls in older women. Arch Intern Med 2008, 168:1768-1775.